Superworth

Agilent Technologies EV/EBIT A

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Nov 3, 2026
30.9×
10-year median
25.6×
Against its 10-year history
81st
percentile: 0 is its lowest day, 100 its highest
10-year range
18.7× to 43.4×
Peer median
32.4×

Agilent Technologies' EV/EBIT is 30.9× as of Nov 3, 2026.

That is above its ten-year median of 25.6×, higher than on 81% of days in the last ten years.

Over that time it ranged from 18.7× in Oct 2023 to 43.4× in Aug 2021.

The median for 10 diagnostics and research stocks of a similar size is 32.4×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far30.9×21.4×31.4×
202526.3×20.0×29.8×
202425.9×19.8×25.9×
202321.4×18.7×29.8×
202228.4×24.1×33.3×
202136.5×31.4×43.4×
202035.5×24.1×41.8×
201929.2×21.9×29.2×
201822.2×21.3×27.9×
201724.9×24.1×28.9×
201623.1×21.9×26.3×
201525.5×24.7×34.3×
201432.1×13.8×32.1×
201314.2×9.2×14.2×
20128.8×6.2×9.0×
20116.4×6.4×16.7×
201015.0×13.3×18.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Agilent Technologies' size, closest first, today.

CompanyEV/EBIT
AAgilent Technologies30.9×
IDXXIDEXX Laboratories36.3×
WATWaters128×
IQVIQVIA25.4×
ILMNIllumina36.6×
MTDMettler-Toledo International30.6×
LHLabcorp22.9×
DGXQuest Diagnostics19.0×
MEDPMedpace30.4×
RVTYRevvity44.2×
DHRDanaher34.2×
Peer median32.4×

Where Agilent Technologies ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Agilent Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.